FDA Update: Now Hiring

The FDA has begun the recruiting process to hire a contractor to study thousands of CBD product samples. This process is one step in a line of many recent FDA activities seeking to help develop regulations for products containing the compound.

On the job posting, the FDA details the position’s requirements to “provide support to the FDA by collecting samples and assessing the quantities of CBD and related cannabinoids, as well as potential associated contaminants such as toxic elements, pesticides, industrial chemicals, processing solvents, and microbial contaminants” present in a range of CBD-infused foods and cosmetics products.

Future Implications

This is not the first study the FDA has conducted. An attachment to the job listing explains that there was previously a smaller sampling study carried out by the Center for Food Safety and Applied Nutrition. It looked at about 200 CBD product samples on the market. The new study will be longer-term with a larger sample set, between 1000 and 3000 samples from across the country. The results of this study will “be reported to congress” and “guide the development of future policy,” the listing states.

“The types of samples to be collected for these studies will include food and cosmetic products from across the United States, mainly including CBD-containing packaged and processed foods such as beverages, water, candy, baked goods, oils and tinctures that can be added to human or animal foods, including pills, capsules, gel caps, gummies and other forms. The analytical methodology for this contract will be defined by the FDA and will include methods based on widely available and recognized methodology.”

The contractor will be expected to utilize liquid and gas chromatography techniques to analyze each sample to determine their cannabinoid make-up as well as any contaminants or harmful elements in the sample, such as heavy metals, pesticides, residual solvents, and microbiological risks such as salmonella contamination.

Applications for this contracting role with the FDA are due by August 31, 10:00 am EDT.

Company Update

You’ve heard us say, time and time again, quality is our first priority. This week, we want to share with you what a weekly batch of distillate looks like at BDX.

This batch came out to a great 87% CBD! If you are interested in any samples or want to see a COA please call us at 317-741-5173 or email us at info@bdxco.com.